



**THE PARTIES**

1  
2           1.       Lilly is an Indiana corporation that has its corporate offices and principal place of  
3 business at Lilly Corporate Center, Indianapolis, Indiana 46285. Lilly is engaged in the business  
4 of research, development, manufacture, and sale of pharmaceutical products throughout the  
5 world.

6  
7           2.       Eli Lilly Export S.A. is a Swiss corporation that has its corporate office at 16  
8 Chemin des Coquelicots, The Air Centre, 1214 Vernier/Geneva, Switzerland. Eli Lilly Export  
9 S.A. is a wholly owned subsidiary of Lilly.

10           3.       Acrux is an Australian corporation that has its corporate offices and principal  
11 place of business at 103-113 Stanley Street, West Melbourne VIC 3003, Australia. Acrux is  
12 engaged in the development and commercialization of pharmaceutical products for sale  
13 throughout the world.

14  
15           4.       Actavis, Inc. is a Nevada corporation with its principal place of business at Morris  
16 Corporate Center III, 400 Interspace Parkway, Parsippany, NJ 07054. Actavis, Inc. is a  
17 pharmaceutical company that develops, manufactures, markets, and distributes generic  
18 pharmaceutical products for sale in the State of Nevada and throughout the United States.

19           5.       Watson Laboratories, Inc. (“Watson Laboratories”) is a Nevada corporation with  
20 its principal place of business at 311 Bonnie Circle, Corona, California 92880. Watson  
21 Laboratories is a pharmaceutical company that develops, manufactures, markets, and distributes  
22 generic pharmaceutical products for sale in the State of Nevada and throughout the United States  
23 in concert with its parent company Actavis, Inc. and related companies.

24  
25           6.       Actavis Pharma, Inc. (“Actavis Pharma”) is a Delaware corporation with its  
26 principal place of business at Morris Corporate Center III, 400 Interspace Parkway, Parsippany,  
27 NJ 07054. Actavis Pharma is a pharmaceutical company that develops, manufactures, markets,  
28

1 and distributes generic pharmaceutical products for sale in the State of Nevada and throughout  
2 the United States in concert with its parent company Actavis, Inc. and related companies.

3 7. Watson Laboratories and Actavis Pharma are wholly owned subsidiaries of  
4 Actavis, Inc. Watson Laboratories, Actavis Pharma, and Actavis, Inc. are collectively referred to  
5 herein as “Actavis.”  
6

7 **NATURE OF THE ACTION**

8 8. This is an action for infringement of U.S. Patent Nos. 6,299,900 (“the ’900  
9 patent”); 6,818,226 (“the ’226 patent”); 6,923,983 (“the ’983 patent”); 8,071,075 (“the ’075  
10 patent”); 8,419,307 (“the ’307 patent”); and 8,435,944 (“the ’944 patent”). This action relates to  
11 Abbreviated New Drug Application (“ANDA”) No. 205328 submitted in the name of Watson  
12 Laboratories to the U.S. Food and Drug Administration (“FDA”) for approval to market a  
13 generic version of Lilly’s Axiron<sup>®</sup> (testosterone) product, which constitutes an action of  
14 infringement under the United States Patent Laws, Title 35 U.S.C. § 100 *et seq.*, including 35  
15 U.S.C. § 271(e)(2).  
16

17 **SUBJECT MATTER JURISDICTION AND VENUE**

18 9. This action arises under the patent laws of the United States, including 35 U.S.C.  
19 § 271, and the Declaratory Judgment Act, 28 U.S.C. §§ 2201 and 2202.

20 10. This Court has subject matter jurisdiction under 28 U.S.C. §§ 1331 and 1338(a).

21 11. Venue is proper in this judicial district under 28 U.S.C. §§ 1391 and 1400(b).  
22

23 **PERSONAL JURISDICTION**

24 12. The Court has personal jurisdiction over Watson Laboratories and Actavis, Inc.  
25 because they are incorporated in the State of Nevada and over all the Defendants because they  
26 regularly and continuously transact business within the State of Nevada. Defendants market and  
27 sell pharmaceutical products throughout the United States, including the State of Nevada.  
28

1 Defendants derive substantial revenue from Nevada drug sales and have availed themselves of  
2 the privilege of conducting business within the State of Nevada.

3 13. According to the website for Actavis, Inc. and its subsidiaries, Actavis “is a  
4 global, integrated specialty pharmaceutical company focused on developing, manufacturing and  
5 distributing generic, brand and biosimilar products.”

6  
7 14. According to Actavis’s 2012 Annual Report Form 10-K (“Actavis’s 2012 Annual  
8 Report”), “On October 31, 2012, Watson Pharmaceuticals, Inc. completed the acquisition of the  
9 Actavis Group. On January 24, 2013, the Company was renamed Actavis, Inc.” The 2012  
10 Annual Report further states that “[f]ollowing the renaming of Watson Pharmaceuticals, Inc. to  
11 Actavis, Inc. efforts are underway to change the underlying ‘Watson’ subsidiary and legal entity  
12 names to an ‘Actavis’ name. This process is expected to continue to roll out throughout the  
13 year.”

14  
15 15. According to Actavis’s 2012 Annual Report, “[t]he Company operates in three  
16 business segments: Actavis Pharma; Actavis Specialty Brands; and Anda Distribution (also  
17 known as ‘Anda’).”

18  
19 16. According to Actavis’s 2012 Annual Report, the “United States of America  
20 (‘U.S.’) remains our largest commercial market and represented approximately 81% of total net  
21 revenues for 2012. As of December 31, 2012, we marketed approximately 250 generic  
22 pharmaceutical product families and over 40 brand pharmaceutical products in the U.S. and  
23 distributed approximately 11,450 stock-keeping units (‘SKUs’) through our Anda Distribution  
24 Division.”

25  
26 17. The 2012 Annual Report further states: “[i]n the U.S., we predominantly market  
27 our generic products to various drug wholesalers, mail order, government and national retail drug  
28 and food store chains utilizing a small team of sales and marketing professionals. We sell our

1 generic prescription products primarily under the ‘Watson Laboratories’, ‘Watson Pharma’ and  
2 ‘Actavis Pharma’ labels, and our over-the-counter generic products under private label.”

3 18. According to Actavis’s 2012 Annual Report: “[i]n our Actavis Pharma and  
4 Actavis Specialty Brand operations, we sell our generic and brand pharmaceutical products  
5 primarily to drug wholesalers, retailers and distributors, including national retail drug and food  
6 store chains, hospitals, clinics, mail order, government agencies and managed healthcare  
7 providers such as health maintenance organizations and other institutions. In our Anda  
8 Distribution business, we distribute generic and certain select brand pharmaceutical products to  
9 independent pharmacies, alternate care providers (hospitals, nursing homes and mail order  
10 pharmacies), pharmacy chains, physicians’ offices and buying groups.”

11 19. According to Actavis’s 2012 Annual Report, “[o]ur Anda Distribution business  
12 primarily distributes generic and selected brand pharmaceutical products, vaccines, injectables  
13 and over-the-counter medicines to independent pharmacies, alternate care providers (hospitals,  
14 nursing homes and mail order pharmacies), pharmacy chains and physicians’ offices.  
15 Additionally, we sell to members of buying groups, which are independent pharmacies that join  
16 together to enhance their buying power. We believe that we are able to effectively compete in the  
17 distribution market, and therefore optimize our market share, based on three critical elements: (i)  
18 competitive pricing, (ii) high levels of inventory for approximately 11,450 SKUs for responsive  
19 customer service that includes, among other things, next day delivery to the entire U.S., and (iii)  
20 well established telemarketing relationships with our customers, supplemented by our electronic  
21 ordering capabilities. While we purchase most of the approximate 11,450 SKUs in our Anda  
22 Distribution operations from third party manufacturers, we also distribute our own products and  
23 our collaborative partners’ products. We are the only U.S. pharmaceutical company that has  
24 meaningful distribution operations with direct access to independent pharmacies.”  
25  
26  
27  
28

1           20.    Upon information and belief, Watson Laboratories, Actavis Pharma, and/or  
2 Actavis, Inc. share common officers and directors.

3           21.    Watson Laboratories, directly or through related companies, has engaged in  
4 substantial and continuous contacts with Nevada that satisfy due process and confer personal  
5 jurisdiction over Watson Laboratories in Nevada on the basis of general jurisdiction.  
6

7           22.    Watson Laboratories develops and manufactures pharmaceutical products for sale  
8 throughout the United States, including the State of Nevada. Watson Laboratories, either  
9 directly or through wholesalers, sells pharmaceutical products to national and regional retail  
10 drug, supermarket, and/or mass merchandise chains in Nevada, and Watson Laboratories derives  
11 substantial revenue from these sales.

12           23.    Actavis, Inc., directly or in concert with related companies, has engaged in  
13 substantial and continuous contacts with Nevada that satisfy due process and confer personal  
14 jurisdiction over Actavis, Inc. in Nevada on the basis of general jurisdiction.  
15

16           24.    Actavis, Inc., either directly or through wholesalers, sells pharmaceutical products  
17 to national and regional retail drug, supermarket, and/or mass merchandise chains in Nevada, and  
18 Actavis, Inc. derives substantial revenue from these sales.

19           25.    Actavis Pharma, directly or in concert with related companies, has engaged in  
20 substantial and continuous contacts with Nevada that satisfy due process and confer personal  
21 jurisdiction over Actavis Pharma in Nevada on the basis of general jurisdiction.  
22

23           26.    Actavis Pharma is a corporation registered with the Nevada Secretary of State as a  
24 corporation that may conduct business in the State of Nevada.

25           27.    Actavis Pharma, either directly or through wholesalers, sells pharmaceutical  
26 products to national and regional retail drug, supermarket, and/or mass merchandise chains in  
27 Nevada, and Actavis Pharma derives substantial revenue from these sales.  
28



1 (commonly known as the “Orange Book”) in connection with Axiron<sup>®</sup>. A true and correct copy  
2 of the ’900 patent is attached as Exhibit A. Acrux is the owner of the ’900 patent. Eli Lilly  
3 Export S.A. is the exclusive licensee worldwide for all uses of Axiron<sup>®</sup> under the ’900 patent.  
4 Eli Lilly Export S.A. has licensed its rights in the ’900 patent to Lilly.  
5

6 **C. The ’226 Patent**

7 32. United States Patent No. 6,818,226 (“the ’226 patent”), entitled “Dermal  
8 Penetration Enhancers and Drug Delivery Systems Involving Same,” was duly and legally issued  
9 by the PTO on November 16, 2004. The ’226 patent claims, *inter alia*, a transdermal drug  
10 delivery system that comprises at least one physiologically active agent and at least one dermal  
11 penetration enhancer. The ’226 patent is listed in the Orange Book in connection with Axiron<sup>®</sup>.  
12 A true and correct copy of the ’226 patent is attached as Exhibit B. Since its date of issue, Acrux  
13 has been, and continues to be, the owner of the ’226 patent. Eli Lilly Export S.A. is the  
14 exclusive licensee worldwide for all uses of Axiron<sup>®</sup> under the ’226 patent. Eli Lilly Export S.A.  
15 has licensed its rights in the ’226 patent to Lilly.  
16

17 **D. The ’983 Patent**

18 33. United States Patent No. 6,923,983 (“the ’983 patent”), entitled “Transdermal  
19 Delivery of Hormones,” was duly and legally issued by the PTO on August 2, 2005. The ’983  
20 patent claims, *inter alia*, a transdermal drug delivery system comprising a therapeutically  
21 effective amount of a hormone and at least one dermal penetration enhancer. The ’983 patent is  
22 listed in the Orange Book in connection with Axiron<sup>®</sup>. A true and correct copy of the ’983  
23 patent is attached as Exhibit C. Since its date of issue, Acrux has been, and continues to be, the  
24 owner of the ’983 patent. Eli Lilly Export S.A. is the exclusive licensee worldwide for all uses  
25 of Axiron<sup>®</sup> under the ’983 patent. Eli Lilly Export S.A. has licensed its rights in the ’983 patent  
26 to Lilly.  
27  
28



1           **E.     The '075 Patent**

2           34.     United States Patent No. 8,071,075 (“the '075 patent”), entitled “Dermal  
3 Penetration Enhancers and Drug Delivery Systems Involving the Same,” was duly and legally  
4 issued by the PTO on December 6, 2011. The '075 patent claims, *inter alia*, a transdermal drug  
5 delivery system comprising a therapeutically effective amount of testosterone and at least one  
6 dermal penetration enhancer. The '075 patent is listed in the Orange Book in connection with  
7 Axiron<sup>®</sup>. A true and correct copy of the '075 patent is attached as Exhibit D. Since its date of  
8 issue, Acrux has been, and continues to be, the owner of the '075 patent. Eli Lilly Export S.A. is  
9 the exclusive licensee worldwide for all uses of Axiron<sup>®</sup> under the '075 patent. Eli Lilly Export  
10 S.A. has licensed its rights in the '075 patent to Lilly.

11           **F.     The '307 Patent**

12           35.     United States Patent No. 8,419,307 (“the '307 patent”), entitled “Spreading  
13 Implement,” was duly and legally issued by the PTO on April 16, 2013. The '307 patent claims,  
14 *inter alia*, a method of increasing the testosterone blood level of a person in need thereof  
15 comprising applying a liquid pharmaceutical composition that contains testosterone. The '307  
16 patent is listed in the Orange Book in connection with Axiron<sup>®</sup>. A true and correct copy of the  
17 '307 patent is attached as Exhibit E. Since its date of issue, Acrux has been, and continues to be,  
18 the owner of the '307 patent. Eli Lilly Export S.A. is the exclusive licensee worldwide for all  
19 uses of Axiron<sup>®</sup> under the '307 patent. Eli Lilly Export S.A. has licensed its rights in the '307  
20 patent to Lilly.

21           **G.     The '944 Patent**

22           36.     United States Patent No. 8,435,944 (“the '944 patent”), entitled “Method and  
23 Composition for Transdermal Drug Delivery,” was duly and legally issued by the PTO on May  
24 7, 2013. The '944 patent claims, *inter alia*, methods of increasing the testosterone blood level of  
25  
26  
27  
28

1 an adult male comprising applying a transdermal drug delivery composition that contains  
2 testosterone. The '944 patent is listed in the Orange Book in connection with Axiron<sup>®</sup>. A true  
3 and correct copy of the '944 patent is attached as Exhibit F. Since its date of issue, Acrux has  
4 been, and continues to be, the owner of the '944 patent. Eli Lilly Export S.A. is the exclusive  
5 licensee worldwide for all uses of Axiron<sup>®</sup> under the '944 patent. Eli Lilly Export S.A. has  
6 licensed its rights in the '944 patent to Lilly.  
7

8 **H. Actavis's ANDA No. 205328**

9 37. Defendants filed or caused to be filed with the FDA ANDA No. 205328 under 21  
10 U.S.C. § 355(j) to obtain approval for the commercial manufacture, use, and sale of  
11 "Testosterone Topical Solution, for Topical Use, 30 mg of Testosterone per Pump Actuation"  
12 ("Actavis's Generic Product") in the United States before the expiration of the '900, '226, '983,  
13 '075, '307, and '944 patents.  
14

15 38. Watson Laboratories, Actavis, Inc., and Actavis Pharma acted in concert to  
16 prepare and submit ANDA No. 205328.

17 39. ANDA No. 205328 contains certifications pursuant to 21 U.S.C.  
18 § 355(j)(2)(A)(vii)(IV) ("paragraph IV certifications"), alleging that the claims of the '900, '226,  
19 '983, '075, '307, and '944 patents are invalid, unenforceable, and/or would not be infringed by  
20 Actavis's Generic Product.  
21

22 40. Defendants sent or caused to be sent to Lilly and Acrux a letter dated October 4,  
23 2013 ("the Notice Letter"), notifying Lilly and Acrux that Defendants' ANDA No. 205328  
24 includes paragraph IV certifications to obtain approval to engage in the commercial manufacture,  
25 use, or sale of Actavis's Generic Product before the expiration of the '900, '226, '983, '075,  
26 '307, and '944 patents, and providing information pursuant to 21 U.S.C. § 355(j)(2)(B).  
27 Defendants' Notice Letter states: "[Watson Laboratories] alleges, and has certified to FDA, that  
28

1 in [Watson Laboratories'] opinion and to the best of its knowledge, the '900, '226, '983, '075,  
2 '397, and '944 patent claims are invalid, unenforceable and/or will not be infringed by the  
3 commercial manufacture, use or sale of the drug product described in [Watson Laboratories']  
4 ANDA.”

5  
6 41. The Notice Letter purported to include an “Offer of Confidential Access” to Lilly  
7 and Acrux to ANDA No. 205328. Under the Federal Food Drug and Cosmetic Act, 21 U.S.C.  
8 § 355(j)(5)(III), restrictions to an Offer of Confidential Access must serve the purpose of  
9 protecting trade secrets and other confidential business information. Actavis’s Offer of  
10 Confidential Access restricted disclosure to outside counsel only and required that such counsel  
11 (a) not be involved in patent prosecution matters, either formally or informally, for Lilly or  
12 Acrux without limitation as to time or subject matter, and (b) not be involved in any FDA  
13 counseling, litigation, or other work before or involving the FDA, without limitation as to time or  
14 subject matter. Actavis’s offer was also restricted to certain unspecified information from its  
15 ANDA.  
16

17 42. The proposed terms of Actavis’s Offer of Confidential Access did not allow  
18 Acrux or Lilly in-house litigation team members who do not engage in patent prosecution  
19 relating to Axiron<sup>®</sup> or development of Axiron<sup>®</sup>, and who are crucial decision makers in the  
20 process of filing any infringement action, access to the necessary information with which to  
21 assess many of the details of Actavis’s proposed generic copy of Axiron<sup>®</sup>. Actavis’s proposed  
22 restrictions to other work performed by those having access to the ANDA were not directed to  
23 the purpose of protecting trade secrets and other confidential business information. Therefore,  
24 Actavis’s Offer of Confidential Access was not on reasonable terms.  
25

26 43. Lilly’s and Acrux’s outside counsel had a series of discussions with Actavis in an  
27 attempt to reach agreement on the terms and conditions of the Offer for Confidential Access;  
28

1 however, the parties did not reach agreement. Lilly and Acrux could not agree to all of the  
2 restrictions Actavis continued to place on its Offer of Confidential Access that were above and  
3 beyond those found in a reasonable protective order or as would be necessary to protect  
4 confidential business information, and Actavis did not provide Lilly or Acrux access to any  
5 portion of Actavis's ANDA.

6  
7 44. The submission of ANDA No. 205328 to the FDA constitutes infringement by  
8 Defendants of the '900, '226, '983, '075, '307, and '944 patents under 35 U.S.C. § 271(e)(2).  
9 Moreover, any commercial manufacture, use, sale, offer for sale, or importation of Actavis's  
10 Generic Product would infringe the '900, '226, '983, '075, '307, and '944 patents under 35  
11 U.S.C. § 271(a), (b), and/or (c).

12  
13 45. Defendants know and intend that physicians will prescribe and patients will take  
14 Actavis's Generic Product for which approval is sought in ANDA No. 205328 and, therefore,  
15 will infringe at least one claim of the patents in suit.

16  
17 46. Defendants had knowledge of the patents-in-suit and, by their promotional  
18 activities associated with Actavis's Generic Product, know or should know that they will aid and  
19 abet another's direct infringement of at least one of the claims of the patents in suit either  
20 literally or under the doctrine of equivalents.

21  
22 47. Defendants plan to make, use, sell, offer to sell, and/or import Actavis's Generic  
23 Product for uses that will infringe the patents-in-suit. Actavis's Generic Product is a material  
part of these infringing uses and has no substantial non-infringing uses.

24  
25 48. Plaintiffs commenced this action within 45 days of receiving Actavis's October 4,  
2013, Notice Letter.

26 ///

27 ///

28

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

**COUNT I FOR PATENT INFRINGEMENT**  
**(Direct Infringement of U.S. Patent No. 6,299,900)**

49. Plaintiffs incorporate by reference and reallege Paragraphs 1-48 above as though fully restated herein.

50. Pursuant to 35 U.S.C. § 271(e)(2), Defendants’ submission of ANDA No. 205328 to the FDA seeking approval of Actavis’s Generic Product before expiration of the ’900 patent was an act of infringement of the ’900 patent by Defendants.

51. If ANDA No. 205328 is approved by the FDA, Defendants’ commercial manufacture, use, offer to sell, sale in the United States, or importation into the United States of Actavis’s Generic Product would directly infringe, either literally or under the doctrine of equivalents, one or more claims of the ’900 patent under 35 U.S.C. § 271.

52. Unless Defendants are enjoined by the Court, Plaintiffs will be substantially and irreparably harmed by Defendants’ infringement of the ’900 patent. Plaintiffs do not have an adequate remedy at law.

**COUNT II FOR PATENT INFRINGEMENT**  
**(Inducement to Infringe U.S. Patent No. 6,299,900)**

53. Plaintiffs incorporate by reference and reallege Paragraphs 1 through 52 above as though fully restated herein.

54. Defendants have knowledge of the ’900 patent.

55. Upon FDA approval of ANDA No. 205328, Defendants will intentionally encourage acts of direct infringement of the ’900 patent by others, with knowledge that their acts are encouraging infringement.

///  
///





1           73. If ANDA No. 205328 is approved by the FDA, Defendants' commercial  
2 manufacture, use, offer to sell, sale in the United States, or importation into the United States of  
3 Actavis's Generic Product would directly infringe, either literally or under the doctrine of  
4 equivalents, one or more claims of the '983 patent under 35 U.S.C. § 271.

5           74. Unless Defendants are enjoined by the Court, Plaintiffs will be substantially and  
6 irreparably harmed by Defendants' infringement of the '983 patent. Plaintiffs do not have an  
7 adequate remedy at law.  
8

9  
10                           **COUNT VIII FOR PATENT INFRINGEMENT**  
                          **(Inducement to Infringe U.S. Patent No. 6,923,983)**

11           75. Plaintiffs incorporate by reference and reallege Paragraphs 1 through 74 above as  
12 though fully restated herein.

13           76. Defendants have knowledge of the '983 patent.

14           77. Upon FDA approval of ANDA No. 205328, Defendants will intentionally  
15 encourage acts of direct infringement of the '983 patent by others, with knowledge that their acts  
16 are encouraging infringement.  
17

18                           **COUNT IX FOR PATENT INFRINGEMENT**  
19                           **(Contributory Infringement of U.S. Patent No. 6,923,983)**

20           78. Plaintiffs incorporate by reference and reallege Paragraphs 1 through 77 above as  
21 though fully restated herein.

22           79. If ANDA No. 205328 is approved, Defendants intend to and will offer to sell, sell,  
23 or import into the United States Actavis's Generic Product.

24           80. Defendants have had and continue to have knowledge that Actavis's Generic  
25 Product is especially adapted for a use that infringes the '983 patent.  
26

27 ///  
28



1 81. Defendants have had and continue to have knowledge that there is no substantial  
2 non-infringing use for Actavis's Generic Product.

3 **COUNT X FOR PATENT INFRINGEMENT**  
4 **(Infringement of U.S. Patent No. 8,071,075)**

5 82. Plaintiffs incorporate by reference and reallege Paragraphs 1-81 above as though  
6 fully restated herein.

7 83. Pursuant to 35 U.S.C. § 271(e)(2), Defendants' submission of ANDA No. 205328  
8 to the FDA seeking approval of Actavis's Generic Product before expiration of the '075 patent  
9 was an act of infringement of the '075 patent by Defendants.

10 84. If ANDA No. 205328 is approved by the FDA, Defendants' commercial  
11 manufacture, use, offer to sell, sale in the United States, or importation into the United States of  
12 Actavis's Generic Product would directly infringe, either literally or under the doctrine of  
13 equivalents, one or more claims of the '075 patent under 35 U.S.C. § 271.

14 85. Unless Defendants are enjoined by the Court, Plaintiffs will be substantially and  
15 irreparably harmed by Defendants' infringement of the '075 patent. Plaintiffs do not have an  
16 adequate remedy at law.

17 **COUNT XI FOR PATENT INFRINGEMENT**  
18 **(Inducement to Infringe U.S. Patent No. 8,071,075)**

19 86. Plaintiffs incorporate by reference and reallege Paragraphs 1 through 85 above as  
20 though fully restated herein.

21 87. Defendants have knowledge of the '075 patent.

22 88. Upon FDA approval of ANDA No. 205328, Defendants will intentionally  
23 encourage acts of direct infringement of the '075 patent by others, with knowledge that their acts  
24 are encouraging infringement.  
25  
26

27 ///

28







**COUNT XIX FOR DECLARATORY JUDGMENT**  
**(Infringement of U.S. Patent No. 6,299,900)**

1  
2  
3 115. Plaintiffs incorporate by reference and reallege Paragraphs 1-114 above as though  
4 fully restated herein.

5 116. This declaratory judgment claim arises under the United States Patent Laws, 35  
6 U.S.C. § 100 *et seq.*, including 35 U.S.C. § 271(a)-(c), and the Declaratory Judgment Act,  
7 28 U.S.C. §§ 2201 and 2202. Subject matter jurisdiction is proper under 28 U.S.C. §§ 1331 and  
8 1338(a).

9 117. Defendants submitted ANDA No. 205328, seeking authorization to commercially  
10 manufacture, use, offer for sale, and sell Actavis's Generic Product in the United States.  
11 Defendants' Generic Product has no substantial non-infringing uses.

12 118. Defendants have made, and will continue to make, substantial preparation in the  
13 United States to manufacture, use, sell, offer to sell, or import Actavis's Generic Product prior to  
14 expiration of the '900 patent.

15 119. Defendants intend to engage in the commercial manufacture, use, sale, or offer for  
16 sale within the United States or importation into the United States of Actavis's Generic Product  
17 upon receipt of final FDA approval of ANDA No. 205328, unless enjoined by the Court.

18 120. Defendants' commercial manufacture, use, sale, or offer for sale within or  
19 importation into the United States of Actavis's Generic Product would infringe one or more  
20 claims of the '900 patent under 35 U.S.C. § 271(a), (b), and/or (c).

21 121. Defendants' threatened actions in actively aiding, abetting, encouraging, and  
22 inducing sales of Actavis's Generic Product would infringe and contribute to or induce direct  
23 infringement of one or more claims of the '900 patent.

24 122. Defendants have had and continue to have knowledge that Actavis's Generic  
25 Product is especially adapted for a use that infringes the '900 patent.  
26  
27  
28

1           123. Defendants have had and continue to have knowledge that there is no substantial  
2 non-infringing use for Actavis's Generic Product.

3           124. There is a justiciable case or controversy between Plaintiffs and Defendants  
4 regarding whether Defendants' commercial manufacture, use, sale, offer for sale, or importation  
5 into the United States of Actavis's Generic Product according to ANDA No. 205328 would  
6 infringe one or more claims of the '900 patent.

7           125. If Defendants' infringement of the '900 patent is not enjoined, Plaintiffs will  
8 suffer substantial and irreparable harm from which there is no remedy at law.  
9

10  
11                                   **COUNT XX FOR DECLARATORY JUDGMENT**  
12                                   **(Infringement of U.S. Patent No. 6,818,226)**

13           126. Plaintiffs incorporate by reference and reallege Paragraphs 1-125 above as though  
14 fully restated herein.

15           127. This declaratory judgment claim arises under the United States Patent Laws, 35  
16 U.S.C. § 100 et seq., including 35 U.S.C. § 271(a)-(c), and the Declaratory Judgment Act, 28  
17 U.S.C. §§ 2201 and 2202. Subject matter jurisdiction is proper under 28 U.S.C. §§ 1331 and  
18 1338(a).

19           128. Defendants submitted ANDA No. 205328, seeking authorization to commercially  
20 manufacture, use, offer for sale, and sell Actavis's Generic Product in the United States.  
21 Defendants' Generic Product has no substantial non-infringing uses.  
22

23           129. Defendants have made, and will continue to make, substantial preparation in the  
24 United States to manufacture, use, sell, offer to sell, or import Actavis's Generic Product prior to  
25 expiration of the '226 patent.

26 ///

27 ///

28

1           130. Defendants intend to engage in the commercial manufacture, use, sale, or offer for  
2 sale within the United States or importation into the United States of Actavis's Generic Product  
3 upon receipt of final FDA approval of ANDA No. 205328, unless enjoined by the Court.

4           131. Defendants' commercial manufacture, use, sale, or offer for sale within or  
5 importation into the United States of Actavis's Generic Product would infringe one or more  
6 claims of the '226 patent under 35 U.S.C. § 271(a), (b), and/or (c).

7           132. Defendants' threatened actions in actively aiding, abetting, encouraging, and  
8 inducing sales of Actavis's Generic Product would infringe and contribute to or induce direct  
9 infringement of one or more claims of the '226 patent.

10           133. Defendants have had and continue to have knowledge that Actavis's Generic  
11 Product is especially adapted for a use that infringes the '226 patent.

12           134. Defendants have had and continue to have knowledge that there is no substantial  
13 non-infringing use for Actavis's Generic Product.

14           135. There is a justiciable case or controversy between Plaintiffs and Defendants  
15 regarding whether Defendants' commercial manufacture, use, sale, offer for sale, or importation  
16 into the United States of Actavis's Generic Product according to ANDA No. 205328 would  
17 infringe one or more claims of the '226 patent.

18           136. If Defendants' infringement of the '226 patent is not enjoined, Plaintiffs will  
19 suffer substantial and irreparable harm from which there is no remedy at law.

20  
21  
22                           **COUNT XXI FOR DECLARATORY JUDGMENT**  
23                           **(Infringement of U.S. Patent No. 6,923,983)**

24           137. Plaintiffs incorporate by reference and reallege Paragraphs 1-136 above as though  
25 fully restated herein.

26           138. This declaratory judgment claim arises under the United States Patent Laws, 35  
27 U.S.C. § 100 et seq., including 35 U.S.C. § 271(a)-(c), and the Declaratory Judgment Act, 28

1 U.S.C. §§ 2201 and 2202. Subject matter jurisdiction is proper under 28 U.S.C. §§ 1331 and  
2 1338(a).

3 139. Defendants submitted ANDA No. 205328, seeking authorization to commercially  
4 manufacture, use, offer for sale, and sell Actavis's Generic Product in the United States.  
5 Defendants' Generic Product has no substantial non-infringing uses.

6 140. Defendants have made, and will continue to make, substantial preparation in the  
7 United States to manufacture, use, sell, offer to sell, or import Actavis's Generic Product prior to  
8 expiration of the '983 patent.

9 141. Defendants intend to engage in the commercial manufacture, use, sale, or offer for  
10 sale within the United States or importation into the United States of Actavis's Generic Product  
11 upon receipt of final FDA approval of ANDA No. 205328, unless enjoined by the Court.

12 142. Defendants' commercial manufacture, use, sale, or offer for sale within or  
13 importation into the United States of Actavis's Generic Product would infringe one or more  
14 claims of the '983 patent under 35 U.S.C. § 271(a), (b), and/or (c).

15 143. Defendants' threatened actions in actively aiding, abetting, encouraging, and  
16 inducing sales of Actavis's Generic Product would infringe and contribute to or induce direct  
17 infringement of one or more claims of the '983 patent.

18 144. Defendants have had and continue to have knowledge that Actavis's Generic  
19 Product is especially adapted for a use that infringes the '983 patent.

20 145. Defendants have had and continue to have knowledge that there is no substantial  
21 non-infringing use for Actavis's Generic Product.

22 146. There is a justiciable case or controversy between Plaintiffs and Defendants  
23 regarding whether Defendants' commercial manufacture, use, sale, offer for sale, or importation  
24

25  
26  
27  
28



1 into the United States of Actavis's Generic Product according to ANDA No. 205328 would  
2 infringe one or more claims of the '983 patent.

3 147. If Defendants' infringement of the '983 patent is not enjoined, Plaintiffs will  
4 suffer substantial and irreparable harm from which there is no remedy at law.

5 **COUNT XXII FOR DECLARATORY JUDGMENT**  
6 **(Infringement of U.S. Patent No. 8,071,075)**

7 148. Plaintiffs incorporate by reference and reallege Paragraphs 1-147 above as though  
8 fully restated herein.

9 149. This declaratory judgment claim arises under the United States Patent Laws, 35  
10 U.S.C. § 100 et seq., including 35 U.S.C. § 271(a)-(c), and the Declaratory Judgment Act, 28  
11 U.S.C. §§ 2201 and 2202. Subject matter jurisdiction is proper under 28 U.S.C. §§ 1331 and  
12 1338(a).

13 144. Defendants submitted ANDA No. 205328, seeking authorization to commercially  
14 manufacture, use, offer for sale, and sell Actavis's Generic Product in the United States.  
15 Defendants' Generic Product has no substantial non-infringing uses.

16 151. Defendants have made, and will continue to make, substantial preparation in the  
17 United States to manufacture, use, sell, offer to sell, or import Actavis's Generic Product prior to  
18 expiration of the '075 patent.

19 152. Defendants intend to engage in the commercial manufacture, use, sale, or offer for  
20 sale within the United States or importation into the United States of Actavis's Generic Product  
21 upon receipt of final FDA approval of ANDA No. 205328, unless enjoined by the Court.

22 153. Defendants' commercial manufacture, use, sale, or offer for sale within or  
23 importation into the United States of Actavis's Generic Product would infringe one or more  
24 claims of the '075 patent under 35 U.S.C. § 271(a), (b), and/or (c).

25  
26  
27  
28

1 154. Defendants' threatened actions in actively aiding, abetting, encouraging, and  
2 inducing sales of Actavis's Generic Product would infringe and contribute to or induce direct  
3 infringement of one or more claims of the '075 patent.

4 155. Defendants have had and continue to have knowledge that Actavis's Generic  
5 Product is especially adapted for a use that infringes the '075 patent.

6 156. Defendants have had and continue to have knowledge that there is no substantial  
7 non-infringing use for Actavis's Generic Product.

8 157. There is a justiciable case or controversy between Plaintiffs and Defendants  
9 regarding whether Defendants' commercial manufacture, use, sale, offer for sale, or importation  
10 into the United States of Actavis's Generic Product according to ANDA No. 205328 would  
11 infringe one or more claims of the '075 patent.

12 158. If Defendants' infringement of the '075 patent is not enjoined, Plaintiffs will  
13 suffer substantial and irreparable harm from which there is no remedy at law.

14  
15  
16 **COUNT XXIII FOR DECLARATORY JUDGMENT**  
17 **(Infringement of U.S. Patent No. 8,419,307)**

18 159. Plaintiffs incorporate by reference and reallege Paragraphs 1-158 above as though  
19 fully restated herein.

20 160. This declaratory judgment claim arises under the United States Patent Laws, 35  
21 U.S.C. § 100 et seq., including 35 U.S.C. § 271(a)-(c), and the Declaratory Judgment Act, 28  
22 U.S.C. §§ 2201 and 2202. Subject matter jurisdiction is proper under 28 U.S.C. §§ 1331 and  
23 1338(a).

24 161. Defendants submitted ANDA No. 205328, seeking authorization to commercially  
25 manufacture, use, offer for sale, and sell Actavis's Generic Product in the United States.  
26 Defendants' Generic Product has no substantial non-infringing uses.  
27  
28

1           162. Defendants have made, and will continue to make, substantial preparation in the  
2 United States to manufacture, use, sell, offer to sell, or import Actavis's Generic Product prior to  
3 expiration of the '307 patent.

4           163. Defendants intend to engage in the commercial manufacture, use, sale, or offer for  
5 sale within the United States or importation into the United States of Actavis's Generic Product  
6 upon receipt of final FDA approval of ANDA No. 205328, unless enjoined by the Court.

7           164. Defendants' commercial manufacture, use, sale, or offer for sale within or  
8 importation into the United States of Actavis's Generic Product would infringe one or more  
9 claims of the '307 patent under 35 U.S.C. § 271(a), (b), and/or (c).

10           165. Defendants' threatened actions in actively aiding, abetting, encouraging, and  
11 inducing sales of Actavis's Generic Product would infringe and contribute to or induce direct  
12 infringement of one or more claims of the '307 patent.

13           166. Defendants have had and continue to have knowledge that Actavis's Generic  
14 Product is especially adapted for a use that infringes the '307 patent.

15           167. Defendants have had and continue to have knowledge that there is no substantial  
16 non-infringing use for Actavis's Generic Product.

17           168. There is a justiciable case or controversy between Plaintiffs and Defendants  
18 regarding whether Defendants' commercial manufacture, use, sale, offer for sale, or importation  
19 into the United States of Actavis's Generic Product according to ANDA No. 205328 would  
20 infringe one or more claims of the '307 patent.

21           169. If Defendants' infringement of the '307 patent is not enjoined, Plaintiffs will  
22 suffer substantial and irreparable harm from which there is no remedy at law.

23 ///

24 ///

25

**COUNT XXIV FOR DECLARATORY JUDGMENT**  
**(Infringement of U.S. Patent No. 8,435,944)**

1  
2  
3 170. Plaintiffs incorporate by reference and reallege Paragraphs 1-169 above as though  
4 fully restated herein.

5 171. This declaratory judgment claim arises under the United States Patent Laws, 35  
6 U.S.C. § 100 et seq., including 35 U.S.C. § 271(a)-(c), and the Declaratory Judgment Act, 28  
7 U.S.C. §§ 2201 and 2202. Subject matter jurisdiction is proper under 28 U.S.C. §§ 1331 and  
8 1338(a).

9 172. Defendants submitted ANDA No. 205328, seeking authorization to commercially  
10 manufacture, use, offer for sale, and sell Actavis's Generic Product in the United States.  
11 Defendants' Generic Product has no substantial non-infringing uses.

12 173. Defendants have made, and will continue to make, substantial preparation in the  
13 United States to manufacture, use, sell, offer to sell, or import Actavis's Generic Product prior to  
14 expiration of the '944 patent.

15 174. Defendants intend to engage in the commercial manufacture, use, sale, or offer for  
16 sale within the United States or importation into the United States of Actavis's Generic Product  
17 upon receipt of final FDA approval of ANDA No. 205328, unless enjoined by the Court.

18 175. Defendants' commercial manufacture, use, sale, or offer for sale within or  
19 importation into the United States of Actavis's Generic Product would infringe one or more  
20 claims of the '944 patent under 35 U.S.C. § 271(a), (b), and/or (c).

21 176. Defendants' threatened actions in actively aiding, abetting, encouraging, and  
22 inducing sales of Actavis's Generic Product would infringe and contribute to or induce direct  
23 infringement of one or more claims of the '944 patent.

24 177. Defendants have had and continue to have knowledge that Actavis's Generic  
25 Product is especially adapted for a use that infringes the '944 patent.  
26  
27  
28

1 178. Defendants have had and continue to have knowledge that there is no substantial  
2 non-infringing use for Actavis's Generic Product.

3 179. There is a justiciable case or controversy between Plaintiffs and Defendants  
4 regarding whether Defendants' commercial manufacture, use, sale, offer for sale, or importation  
5 into the United States of Actavis's Generic Product according to ANDA No. 205328 would  
6 infringe one or more claims of the '944 patent.

7  
8 180. If Defendants' infringement of the '944 patent is not enjoined, Plaintiffs will  
9 suffer substantial and irreparable harm from which there is no remedy at law.

10 **PRAYER FOR RELIEF**

11 WHEREFORE, Plaintiffs respectfully request that this Court enter judgment in their  
12 favor as follows:

- 13 a) United States Patent Nos. 6,299,900; 6,818,226; 6,923,983; 8,071,075; 8,419,307;  
and 8,435,944 are valid and enforceable;
- 14 b) Under 35 U.S.C. § 271(e)(2)(A), Defendants infringed United States Patent Nos.  
15 6,299,900; 6,818,226; 6,923,983; 8,071,075; 8,419,307; and 8,435,944 by  
submitting ANDA No. 205328 to the FDA to obtain approval to commercially  
16 manufacture, use, offer for sale, sell, or import into the United States Actavis's  
Generic Product prior to expiration of said patents;
- 17 c) Defendants' threatened acts of commercial manufacture, use, offer for sale, or  
18 sale in, or importation into, the United States of Actavis's Generic Product prior  
to the expiration of United States Patent Nos. 6,299,900; 6,818,226; 6,923,983;  
8,071,075; 8,419,307; and 8,435,944 would constitute infringement of said  
19 patents;
- 20 d) The effective date of any FDA approval of Actavis's Generic Product shall be no  
earlier than the latest of the expiration date of United States Patent Nos.  
21 6,299,900; 6,818,226; 6,923,983; 8,071,075; 8,419,307; and 8,435,944 and any  
additional periods of exclusivity, in accordance with 35 U.S.C. § 271(e)(4)(A);
- 22 e) Defendants, and all persons acting in concert with Defendants, shall be enjoined  
from commercially manufacturing, using, offering for sale, or selling Actavis's  
23 Generic Product within the United States, or importing Actavis's Generic Product  
into the United States, until the expiration of United States Patent Nos. 6,299,900;  
24 6,818,226; 6,923,983; 8,071,075; 8,419,307; and 8,435,944, in accordance with  
35 U.S.C. §§ 271(e)(4)(B) and 283;
- 25 f) This is an exceptional case and Plaintiffs should be awarded their costs, expenses,  
and disbursements in this action, including reasonable attorney fees, pursuant to  
26 35 U.S.C. §§ 285 and 271(e)(4);
- 27 g) Plaintiffs are entitled to any further appropriate relief under 35 U.S.C.  
§ 271(e)(4); and  
28

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

h) Plaintiffs are entitled to any further and additional relief that this Court deems just and proper.

Respectfully submitted,

DATED this 14h day of November 2013.

GORDON SILVER

By: /s/ Molly M. Rezac  
GORDON SILVER  
MOLLY M. REZAC, ESQ.  
Nevada Bar No. 7435  
JUSTIN J. BUSTOS, ESQ.  
Nevada Bar No. 10320  
100 W. Liberty Street, Suite 940  
Reno, NV 89501  
Tel: (775) 343-7500  
Fax: (775) 786-0131

*Of counsel:*  
CHARLES E. LIPSEY  
L. SCOTT BURWELL  
FINNEGAN, HENDERSON, FARABOW,  
GARRETT & DUNNER, LLP  
Two Freedom Square  
11955 Freedom Drive  
Reston, VA 20190-5675  
(571) 203-2700

LAURA P. MASUROVSKY  
AMANDA K. MURPHY  
DANIELLE A. DUSZCZYSZYN  
FINNEGAN, HENDERSON, FARABOW,  
GARRETT & DUNNER, LLP  
901 New York Avenue, NW  
Washington, DC 20001-4413  
(202) 408-4000  
ALISSA K. LIPTON  
FINNEGAN, HENDERSON, FARABOW,  
GARRETT & DUNNER, LLP  
Two Seaport Lane  
Boston, MA 02210-2001  
(617) 646-1600

*Attorneys for Plaintiffs*